Recent U.S., Canadian and British regulatory agency actions concerning antidepressant-induced harm to self and others: A review and analysis

International Journal of Risk and Safety in Medicine

Volumn 16, Issue 4, 2004, Pages 247-259

  Breggin, Peter R ^a  

^a Intl Ctr Stud Psychiat Psychol   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IMIPRAMINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

AGGRESSION; AGITATION; AKATHISIA; ANOREXIA; ANXIETY DISORDER; AUTOMUTILATION; BEHAVIOR DISORDER; CANADA; CLINICAL OBSERVATION; CLINICAL TRIAL; DEPERSONALIZATION; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE EXACERBATION; DRUG INDUCED DISEASE; DRUG INDUSTRY; DRUG LABELING; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; EUPHORIA; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HAZARD; HOSTILITY; HUMAN; HYPOMANIA; IMPULSIVENESS; INSOMNIA; IRRITABILITY; MANIA; MEDICAL DOCUMENTATION; MENTAL DISEASE; MENTAL INSTABILITY; NERVOUSNESS; PANIC; PRESCRIPTION; PSYCHOMOTOR DISORDER; PSYCHOSIS; RESTLESSNESS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; STIMULANT SYNDROME; STIMULATION; SUICIDAL BEHAVIOR; SUICIDE ATTEMPT; TREATMENT CONTRAINDICATION; UNITED KINGDOM; UNITED STATES; VIOLENCE;

EID: 17244379336     PISSN: 09246479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th edn, Text Revision (DSM-IV-TR), American Psychiatric Association, Washington, DC, 2000.
2. P. Breggin, A case of fluoxetine-induced stimulant side effects with suicidal ideation associated with a possible withdrawal syndrome ("crashing"), International Journal of Risk & Safety in Medicine 3 (1992), 325-328.
3. P. Breggin, Brain-Disabling Treatments in Psychiatry: Drugs, Electroshock, and the Role of the FDA, Springer, New York, 1997.
4. P. Breggin, Fluvoxamine as a cause of stimulation, mania, and aggression with a critical analysis of the FDA-approved label, International Journal of Risk and Safety in Medicine 14 (2002), 71-86.
5. P. Breggin, Prozac "hazardous" to children, Clinical Psychiatry News 23 (1995), 10.
6. P. Breggin, Suicidality, violence and mania caused by selective serotonin reuptake inhibitors (SSRIs): A review and analysis, International Journal of Risk and Safety in Medicine 16 (2003/2004), 31-49.
7. P. Breggin, The Antidepressant Fact Book, Perseus Books, Cambridge, MA, 2001.
8. P. Breggin (2004, September 13), Presentation at a Public Hearing of the Food and Drug Administration (FDA). Transcript of Meeting of the Center for Drug Evaluation and Research, pp. 353-354. Joint meeting of the CDER Psychopharmacologic Drugs Advisory Committee and the FDA Pediatric Advisory Committee. Bethesda, Maryland. www.fda.gov.
9. P. Breggin and G. Breggin, Talking Back to Prozac: What Doctors Aren't Telling You about Today's Most Controversial Drug, St. Martin's Press, New York, 1994.
10. P. Chesney (2004, September 13), Remarks by P. Joan Chesney, M.D., member of the Pediatric Advisory Committee, p. 187. Food and Drug Administration. Transcript of Meeting. Center for Drug Evaluation and Research. Joint meeting of the CDER Psychopharmacologic Drugs Advisory Committee and the FDA Pediatric Advisory Committee. Bethesda, Maryland. www.fda.com.
11. G.J. Emslie, Prozac for kids: "Landmark" study affirms drug's use, Clinical Psychiatry News 23 (1995), 1.
12. G.J. Emslie, J.H. Heiligenstein, K.D. Wagner, S.L. Hoog, D.E. Ernest, E. Brown, M. Nilsson and J.G. Jacobson, Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled randomized clinical trial, Journal of the American Academy of Child and Adolescent Psychiatry 41 (2002), 1205-1215.
13. G.J. Emslie, A.J. Rush, W.A. Weinberg, R.A. Kowatch, C.W. Hughes, T. Carmody and T.J. Rintelmann, A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression, Archives of General Psychiatry 54 (1997), 1031-1037.
14. Food and Drug Administration (FDA), FDA issues Public Health Advisory on cautions for use of antidepressants in adults and children, Rockville, Maryland (2004, March 22). www.fda.gov.
15. Food and Drug Administration (FDA), Transcript of Meeting of the Center for Drug Evaluation and Research. Joint meeting of the CDER Psychopharmacologic Drugs Advisory Committee and the FDA Pediatric Advisory Committee. Bethesda, Maryland (2004, September 14). www.fda.gov.
16. Food and Drug Administration (FDA), Labeling change request letter for antidepressant medication. Rockville, Maryland (2004, October 15). www.fda.gov.
17. Food and Drug Administration (FDA), FDA proposed medication guide: about using antidepressants in children or teenagers. Rockville, Maryland (2004, November 3). www.fda.gov.
18. T. Hammad, Results of analysis of suicidality in pediatric trials in newer antidepressants. Delivered at the Center for Drug Evaluation and Research. Joint meeting of the CDER Psychopharmacologic Drugs Advisory Committee and the FDA Pediatric Advisory Committee. Bethesda, Maryland (2004, September 13).
19. Health Canada Online, Advisory: Health Canada advises Canadians of stronger warnings for SSRIs and other newer antidepressants (2004, June 3). www.hc-sc.ca/English/protection/warnings/2004/2004_31.htm.
20. D. Healy, Letter from David Healy, M.D. to Peter J. Pitts, Association Commissioner for External Relations, Food and Drug Administration - Re: Suicidal evidence not addressed by FDA (2004, February 19). www.ahrp.org.
21. D. Healy and C. Whitaker, Antidepressants and suicide: Risk-benefit conundrums, Journal of Psychiatry and Neuroscience 28 (2003), 331-339.
22. http://www.mhra.gov.uk/news/2004/AnnexD.pdf.
23. J. Jureidini, C. Doecke, P. Mansfield, M. Haby, D. Menkes and A. Tonkin, Efficacy and safety of antidepressants for children and adolescents, British Medical Journal 328 (2004), 879-883.
24. M. Keller, N. Ryan, M. Strober, R. Klein, S. Kutcher, B. Birmaher, G. Emslie, K. Wagner, E.B. Weller, N.C. Winters, R. Oakes and J.P. McCafferty, Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial, J. Am. Acad. Child. Adolesc. Psychiatry 40 (2001), 762-772.
25. A. Khan, S. Kahn, R. leventhal and W. Brown, Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration database, International Journal of Neuropsychopharmacology 4 (2001), 113-118.
26. A. Khan, H. Warner and W. Brown, Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials, Archives of General Psychiatry 57 (2000), 311-317.
27. I. Kirsch, T. Moore, A. Scoboria and S. Nicholls, The emperor's new drugs: an analysis of antidepressant medication data submitted to the US Food and Drug Administration, Prevention and Treatment 5 (2002), Article 23. www.journals.apa.org/prevention/volume5/pre0050023a.html.
28. T. Laughren, Regulatory background on antidepressants and suicidality in pediatric patients. Delivered at the Center for Drug Evaluation and Research. Joint meeting of the CDER Psychopharmacologic Drugs Advisory Committee and the FDA Pediatric Advisory Committee. Bethesda, Maryland (2004, September 13).
29. J. Lenzer, Documents missing from a 10 year old murder case sent to the BMJ, British Medical Journal 329 (2004), 1365.
30. L. Marangell, S. Yudofsky and J. Silver, Psychopharmacology and electroconvulsive therapy, in: The American Psychiatric Press Textbook of Psychiatry, R. Hales, S. Yudofsky and J. Talbott, eds, 3rd edn, American Psychiatric Press, Washington, DC, 1999, Chapter 27.
31. MHRA, [Medicines and Healthcare products Regulatory Agency, Great Britain]. Questions and Answers: Advice on SSRIs in children from the Committee on Safety of Medicines. Updated February 12, 2004. www.mhra.gov.uk.
32. MHRA, [Medicines and Healthcare products Regulatory Agency, Great Britain]. Suicidal thoughts/behavior. December 6, 2004. www.mhra.gov.uk.
33. T. Moore, Antidepressant drugs and suicidal/aggressive behaviors (2004, January 6). 2021 K Street NW, Suite 800, Washington, DC 20006. www.DrugSafetyResearch.com.
34. A.D. Mosholder, Suicidality in pediatric clinical trials with paroxetine and other antidepressant drugs. Memo from Mosholder to Russell Katz, Director, Division of Neurophamiacological Drug Products. Rockville Maryland: Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (2004, February 18). www.ahrp.org.
35. A.D. Mosholder, Comparison between original ODS and Current DNDP analyses of pediatric suicidality data sets. Delivered at the Meeting of Psychopharmacological Drugs Advisory Committee and Pediatric Drugs Advisory Committee on September 13, 2004, Bethesda, Maryland.
36. Pfizer Canada Inc., Stronger WARNING for SSRIs and other new antidepressants regarding the potential for behavioral and emotional changes including risk of self harm (2004, May 26). www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/ Zoloft.
37. C. Whittington, T. Kendall, P. Fonagy, D. Cottrell and E. Boddington, Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data, Lancet 363 (2004), 1341-1345.